AbbVie Inc. (ABBV) vs AMGEN INC (AMGN)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ABBV | AMGN |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $61.16B | $36.75B |
| Revenue growth (YoY) | ▲ 8.6% | ▲ 10.0% |
| Net income | $4.23B | $7.71B |
| Gross margin | 70.2% | 67.2% |
| Diluted EPS | $2.36 | $14.23 |
| Insider net (6 mo) | +12.3K sh • 1 sells • 0 buys | +15.3K sh • 5 sells • 0 buys |
| Institutional owners | 46 | 46 |
| Institutional value held | $222.87B | $113.58B |
| Next earnings (est.) | Around Feb 3, 2027 | Nov 3, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About AbbVie Inc. (ABBV)
AbbVie Inc., incorporated in Delaware in 2012, is a global, diversified research-based biopharmaceutical company that became an independent, publicly-traded entity on January 1, 2013, following its spin-off from Abbott Laboratories. Read more →
About AMGEN INC (AMGN)
Amgen Inc. is a global biotechnology company, incorporated in California in 1980 and reincorporated in Delaware in 1987, that discovers, develops, manufactures, and delivers innovative medicines targeting areas of high unmet medical need, operating as a… Read more →
Source: SEC EDGAR.